Healthcare insurance company Molina Healthcare (NYSE: MOH) met Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 3.1% year on year to $10.8 billion. On the other hand, the company’s full-year revenue guidance of $42 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $2.35 per share was 23% above analysts’ consensus estimates.

Is now the time to buy MOH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Molina Healthcare’s first quarter results were marked by disciplined medical cost management and ongoing adaptation to a shifting Medicaid landscape. CEO Joseph Zubretsky described the quarter as “solid under the circumstances,” emphasizing the company’s 91.1% consolidated medical cost ratio and a 1.6% adjusted pretax margin. Management attributed performance to favorable medical cost trends and effective protocols in response to last year’s higher acuity shifts from Medicaid redeterminations. Zubretsky noted, “Our expectation that the acuity shift trend that we had experienced in 2025 was behind us and would not recur is holding up.”

Looking forward, Molina Healthcare’s strategy centers on maintaining prudent cost controls and monitoring regulatory developments, particularly around Medicaid eligibility and rate updates. Management reaffirmed full-year adjusted EPS guidance, with Zubretsky stating, “Merely reaffirming our prior full year guidance is a prudent approach at this early point in the year and in this current environment.” The company expects that any further Medicaid membership declines will have minimal impact on acuity, while potential off-cycle and retroactive rate increases from states could provide upside. Management also highlighted ongoing efforts to optimize the Florida CMS Kids contract and further integrate dual Medicare-Medicaid offerings, which they believe will support margin expansion over the next several years.

Key Insights from Management’s Remarks

Management pointed to effective medical cost containment, Medicaid membership shifts, and cautious marketplace exposure as the primary forces behind Q1’s results. The quarter also reflected strategic progress in refining product mix and operational execution.

• Disciplined medical cost management: The company’s focus on tightening medical cost protocols led to a consolidated medical cost ratio (MCR) of 91.1%. Management stressed that previous concerns about rising acuity—where higher-cost patients represent a larger share due to redeterminations—have largely subsided, as most low and no utilizers have already exited Medicaid rolls.

• Medicaid membership declines: Management noted higher-than-expected attrition in key states like California, Illinois, and New York, particularly among undocumented immigrant populations. However, they emphasized that the impact on overall medical cost trends is limited, as the remaining population profile is more predictable and stable.

• Marketplace segment stability: Molina’s decision to reduce exposure in the volatile ACA Marketplace segment contributed to a more stable member base, with 70% of members now renewals and a continued focus on the silver tier. This shift is intended to prioritize margin over volume, mitigating risk from regulatory changes and competitive pricing pressures.

• Strong start for dual Medicare-Medicaid products: The integration of former MMP members into new dual-eligible offerings (HIDE and FIDE) outperformed initial internal expectations. Management believes these integrated products will enhance Molina’s competitive position as states increasingly promote Medicaid-Medicare integration.

• Florida CMS Kids contract ramp: The company is in full implementation mode for the $6 billion Florida CMS Kids contract, emphasizing its expertise in managing high-acuity and behavioral health costs. Management expects this contract to be a meaningful contributor to embedded earnings over the next two years.

Drivers of Future Performance

Molina’s outlook is shaped by disciplined expense management, ongoing Medicaid rate updates, and a focus on margin expansion as the regulatory and membership environment evolves.

• Medicaid rate updates and policy shifts: Management anticipates that states may provide off-cycle and retroactive rate adjustments to catch up with persistent medical cost inflation. These increases could support margins, particularly as states adapt to cost inflections and update actuarial data. However, states are also tightening eligibility requirements and considering work/community engagement mandates, which could further impact enrollment and operational complexity.

• Margin expansion from product mix: The company’s move away from higher-risk Marketplace segments and toward integrated dual Medicare-Medicaid offerings is expected to improve margin stability. Management highlighted the potential for improved profitability as Molina exits loss-making MAPD products and focuses on duals, where the regulatory landscape increasingly favors integration and coordinated care.

• Execution on new contracts and growth initiatives: The successful ramp of the Florida CMS Kids contract and future M&A activity remain key to revenue growth. Management emphasized that new contract wins, such as Florida CMS, and disciplined acquisition opportunities are expected to drive incremental earnings power and support long-term financial targets.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will be watching (1) the pace and magnitude of Medicaid rate increases and how states implement work or community engagement requirements, (2) margin performance as Molina shifts its product mix and executes on new dual-eligible and Florida CMS contracts, and (3) the sustainability of medical cost trends and any signs of renewed volatility in utilization. The trajectory of M&A activity and further regulatory developments will also be critical areas of focus.

Molina Healthcare currently trades at $173.20, up from $152.70 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.